FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161125717> ?p ?o ?g. }

• W2161125717 endingPage "1816" @default.
• W2161125717 startingPage "1811" @default.
• W2161125717 abstract "Background: The aim of the present study was to evaluate the clinical activity of imatinib mesylate in patients with recurrent and refractory c-kit-expressing small-cell lung cancer.Patients and methods: Patients with c-kit-expressing SCLC (≥1+ by immunohistochemistry) were enrolled in two groups. Arm A included patients with disease progression <3 months and arm B included patients with disease progression ≥3 months after previous treatment. Imatinib was administered at a dose of 400 mg b.i.d. continuously, with a cycle length of 28 days. A single stage Simon design with a planned interim analysis was used to evaluate the 16-week progression free rate in each arm.Results: A total of 29 evaluable patients were entered into the study (seven in arm A, median age 68; 22 in arm B, median age 64.5). Median number of treatment cycles was one in both arms. Grade 3+ non-hematologic adverse events were seen in 15 (52%) patients, with nausea, vomiting, dyspnea, fatigue, anorexia and dehydration each occurring in at least 10% of patients. Median survival was 3.9 and 5.3 months and median time to progression was 1 and 1.1 months for arms A and B, respectively. Enrollment to arm A was temporarily suspended prior to reaching interim analysis due to striking early disease progression (29%), early deaths (29%) and patient refusal (42%). No objective responses and no confirmed stable disease ≥6 weeks were seen in either arm. Accrual was permanently terminated to both arms as only one patient was progression-free at 16 weeks.Conclusion: Imatinib failed to demonstrate any clinical activity in spite of patient selection for c-kit-expressing SCLC. Our results strengthen the collective evidence that prediction of efficacy of novel therapeutic agents based on target expression, rather than pathway activation (for example, through activating mutations), may not be a valid paradigm for drug development." @default.
• W2161125717 created "2016-06-24" @default.
• W2161125717 creator A5002528975 @default.
• W2161125717 creator A5010162250 @default.
• W2161125717 creator A5011536574 @default.
• W2161125717 creator A5025646273 @default.
• W2161125717 creator A5041114807 @default.
• W2161125717 creator A5051786877 @default.
• W2161125717 creator A5058147268 @default.
• W2161125717 creator A5066001765 @default.
• W2161125717 creator A5073163802 @default.
• W2161125717 date "2005-11-01" @default.
• W2161125717 modified "2023-10-18" @default.
• W2161125717 title "A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study" @default.
• W2161125717 cites W1522189913 @default.
• W2161125717 cites W1919288105 @default.
• W2161125717 cites W1932169383 @default.
• W2161125717 cites W2000998080 @default.
• W2161125717 cites W2006230590 @default.
• W2161125717 cites W2012952884 @default.
• W2161125717 cites W2015015957 @default.
• W2161125717 cites W2015551422 @default.
• W2161125717 cites W2029409133 @default.
• W2161125717 cites W2031956553 @default.
• W2161125717 cites W2038110873 @default.
• W2161125717 cites W2038596108 @default.
• W2161125717 cites W2043696829 @default.
• W2161125717 cites W2068466600 @default.
• W2161125717 cites W2073700431 @default.
• W2161125717 cites W2073937802 @default.
• W2161125717 cites W2088145632 @default.
• W2161125717 cites W2112237195 @default.
• W2161125717 cites W2116665983 @default.
• W2161125717 cites W2134094496 @default.
• W2161125717 cites W2138647235 @default.
• W2161125717 cites W2139248078 @default.
• W2161125717 cites W2154169171 @default.
• W2161125717 cites W2161821474 @default.
• W2161125717 cites W2328017321 @default.
• W2161125717 cites W4293241248 @default.
• W2161125717 doi "https://doi.org/10.1093/annonc/mdi365" @default.
• W2161125717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16087693" @default.
• W2161125717 hasPublicationYear "2005" @default.
• W2161125717 type Work @default.
• W2161125717 sameAs 2161125717 @default.
• W2161125717 citedByCount "137" @default.
• W2161125717 countsByYear W21611257172012 @default.
• W2161125717 countsByYear W21611257172013 @default.
• W2161125717 countsByYear W21611257172014 @default.
• W2161125717 countsByYear W21611257172015 @default.
• W2161125717 countsByYear W21611257172016 @default.
• W2161125717 countsByYear W21611257172017 @default.
• W2161125717 countsByYear W21611257172018 @default.
• W2161125717 countsByYear W21611257172019 @default.
• W2161125717 countsByYear W21611257172020 @default.
• W2161125717 countsByYear W21611257172021 @default.
• W2161125717 countsByYear W21611257172022 @default.
• W2161125717 countsByYear W21611257172023 @default.
• W2161125717 crossrefType "journal-article" @default.
• W2161125717 hasAuthorship W2161125717A5002528975 @default.
• W2161125717 hasAuthorship W2161125717A5010162250 @default.
• W2161125717 hasAuthorship W2161125717A5011536574 @default.
• W2161125717 hasAuthorship W2161125717A5025646273 @default.
• W2161125717 hasAuthorship W2161125717A5041114807 @default.
• W2161125717 hasAuthorship W2161125717A5051786877 @default.
• W2161125717 hasAuthorship W2161125717A5058147268 @default.
• W2161125717 hasAuthorship W2161125717A5066001765 @default.
• W2161125717 hasAuthorship W2161125717A5073163802 @default.
• W2161125717 hasBestOaLocation W21611257171 @default.
• W2161125717 hasConcept C126322002 @default.
• W2161125717 hasConcept C141071460 @default.
• W2161125717 hasConcept C197934379 @default.
• W2161125717 hasConcept C2776256026 @default.
• W2161125717 hasConcept C2776694085 @default.
• W2161125717 hasConcept C2777583451 @default.
• W2161125717 hasConcept C2778729363 @default.
• W2161125717 hasConcept C2778822529 @default.
• W2161125717 hasConcept C2780580376 @default.
• W2161125717 hasConcept C3019892230 @default.
• W2161125717 hasConcept C31760486 @default.
• W2161125717 hasConcept C535046627 @default.
• W2161125717 hasConcept C61943457 @default.
• W2161125717 hasConcept C71924100 @default.
• W2161125717 hasConcept C90924648 @default.
• W2161125717 hasConceptScore W2161125717C126322002 @default.
• W2161125717 hasConceptScore W2161125717C141071460 @default.
• W2161125717 hasConceptScore W2161125717C197934379 @default.
• W2161125717 hasConceptScore W2161125717C2776256026 @default.
• W2161125717 hasConceptScore W2161125717C2776694085 @default.
• W2161125717 hasConceptScore W2161125717C2777583451 @default.
• W2161125717 hasConceptScore W2161125717C2778729363 @default.
• W2161125717 hasConceptScore W2161125717C2778822529 @default.
• W2161125717 hasConceptScore W2161125717C2780580376 @default.
• W2161125717 hasConceptScore W2161125717C3019892230 @default.
• W2161125717 hasConceptScore W2161125717C31760486 @default.
• W2161125717 hasConceptScore W2161125717C535046627 @default.
• W2161125717 hasConceptScore W2161125717C61943457 @default.
• W2161125717 hasConceptScore W2161125717C71924100 @default.

• next